Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers curative potential for high-risk hematologic disorders.
• Immune-mediated complications, particularly acute graft-versus-host disease (aGVHD), pose significant risks following allo-HSCT.
• aGVHD occurs when the donor immune system attacks host tissues, necessitating immunosuppressive strategies.

Purpose of the Study:

• To review the clinical features and complex immunobiology of aGVHD.
• To discuss current immunosuppressive therapies for aGVHD prophylaxis and treatment.
• To explore strategies for mitigating side effects and managing other immune-mediated complications post-allo-HSCT.

Main Methods:

• Review of clinical features of aGVHD.
• Discussion of the immunobiology of aGVHD.
• Analysis of immunosuppressive therapies and their management.

Main Results:

• aGVHD remains a significant cause of nonrelapse mortality despite prophylaxis.
• Immunosuppressive agents are crucial for preventing and treating aGVHD.
• Management of immunosuppression requires careful consideration of side effects and other immune complications.

Conclusions:

• Understanding aGVHD's immunobiology is key to effective management.
• Optimizing immunosuppressive strategies is vital for improving allo-HSCT outcomes.
• Comprehensive management addresses aGVHD and other immune-mediated complications.